๐ ๐๐ ๐๐ฅ๐๐๐ซ๐ฌ ๐๐ฎ๐ฆ๐ข๐๐ก๐๐ซ๐โ๐ฌ ๐๐๐ฅ๐๐๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ซ ๐๐ซ๐ฒ ๐๐๐...
๐
๐๐ ๐๐ฉ๐ฉ๐ซ๐จ๐ฏ๐๐ฌ ๐๐๐ฎ๐ซ๐จ๐ญ๐๐๐กโ๐ฌ ๐๐๐๐๐๐๐ ๐๐๐ฅ๐ฅ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ซ ๐๐๐๐๐๐ฅ
๐ The FDA has approved Neurotech Pharmaceuticals, Inc. Pharmaceuticals' ENCELTO (revakinagene taroretcel-lwey), the first treatment for macular telangiectasia type 2 (MacTel)โa progressive retinal disease causing vision loss.
๐จโโ๏ธ ENCELTO uses Encapsulated Cell Therapy (ECT), implanting genetically engineered cells that continuously release ciliary neurotrophic factor (CNTF) to slow retinal degeneration. Phase 3 trials showed significant preservation of macular photoreceptors over 24 months.
๐ Neurotechโs CEO hailed the approval as a milestone, and experts believe ENCELTO will help patients maintain functional vision. The treatment is expected to launch in the U.S. by June 2025.
๐ The FDA has approved Neurotech Pharmaceuticals, Inc. Pharmaceuticals' ENCELTO (revakinagene taroretcel-lwey), the first treatment for macular telangiectasia type 2 (MacTel)โa progressive retinal disease causing vision loss.
๐จโโ๏ธ ENCELTO uses Encapsulated Cell Therapy (ECT), implanting genetically engineered cells that continuously release ciliary neurotrophic factor (CNTF) to slow retinal degeneration. Phase 3 trials showed significant preservation of macular photoreceptors over 24 months.
๐ Neurotechโs CEO hailed the approval as a milestone, and experts believe ENCELTO will help patients maintain functional vision. The treatment is expected to launch in the U.S. by June 2025.
